CSIMarket
 
Mind Medicine mindmed Inc   (NASDAQ: MNMD)
Other Ticker:  
 
 
Price: $8.6500 $0.14 1.645%
Day's High: $9.18 Week Perf: 4.72 %
Day's Low: $ 8.17 30 Day Perf: 35.26 %
Volume (M): 4,705 52 Wk High: $ 12.22
Volume (M$): $ 40,702 52 Wk Avg: $7.48
Open: $8.68 52 Wk Low: $4.39



 Market Capitalization (Millions $) 694
 Shares Outstanding (Millions) 80
 Employees 41
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -98
 Cash Flow (TTM) (Millions $) 178
 Capital Exp. (TTM) (Millions $) 0

Mind Medicine Mindmed Inc
Mind Medicine (MindMed) Inc. is a biotechnology company that focuses on the development of psychedelic medicines. They aim to address mental health disorders and addiction through innovative therapeutic approaches. MindMed is researching and developing psychedelic substances like psilocybin, LSD, and MDMA for use in therapeutic settings. By harnessing the potential of these substances, they hope to provide effective and alternative treatments for various mental health conditions. Their goal is to revolutionize the field of psychiatry and improve the lives of individuals suffering from these disorders.


   Company Address: One World Trade Center New York 10007 NY
   Company Phone Number: 220-6633   Stock Exchange / Ticker: NASDAQ MNMD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALZN   -5.26%    
ANRO   -10.68%    
ATAI        4.13% 
BICX        4.13% 
CMPS        0.23% 
SAGE   -0.97%    
• View Complete Report
   



Business Update

MindMed Set to Join Nasdaq Biotechnology Index Following Successful Year,

Published Thu, Dec 19 2024 2:03 PM UTC

MindMed to Join Nasdaq Biotechnology Index Amid Transformational Year NEW YORK - Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), a pioneering clinical-stage biopharmaceutical company specializing in innovative treatments for brain health disorders, announced today that it will be added to the Nasdaq Biotechnology Index (NBI) starting at market open on December 23, 2024. This ...

Business Update

MindMeds Breakthrough Journey Advancements in Anxiety Disorder Treatment and Market Recognition

Published Mon, Dec 16 2024 3:03 PM UTC

In an era marked by an increased focus on mental health, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), is making significant strides in the development of innovative treatments for brain health disorders. Recently, the company achieved a pivotal milestone by dosing its first patient in the Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized formulation of lysergid...

Business Update

MindMed Secures Patent for Revolutionary MM120 Orally Disintegrating Tablet, Paving the Way for Advanced Anxiet...

Published Wed, Jul 17 2024 12:47 PM UTC

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a trailblazer in the realm of biopharmaceuticals, announced today the issuance of a new patent by the United States Patent and Trademark Office (USPTO) for its groundbreaking MM120 Orally Disintegrating Tablet (ODT). The patent fortifies MindMed s intellectual property portfolio, enhancing its position as a leader in the developme...

Business Update

MindMed Breaks New Ground with Inclusion in Russell Indexes, Presents Impact Studies on GAD, and Celebrates Positive ...

Published Fri, Jun 28 2024 12:47 PM UTC

MindMed, a clinical stage biopharmaceutical company focused on developing innovative treatments for brain health disorders, has achieved a significant milestone with its inclusion in the Russell 2000 Index and the Russell 3000 Index. This announcement comes alongside new studies presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR ...

Business Update

MindMeds Positive FDA Meeting Brings Hope for Groundbreaking Treatment of Generalized Anxiety Disorder

Published Thu, Jun 20 2024 11:47 AM UTC

MindMed Advances Novel Treatment for Generalized Anxiety Disorder with Positive FDA MeetingMind Medicine (MindMed) Inc., a pioneering biopharmaceutical company focused on developing innovative therapies for brain health disorders, has announced a significant milestone in the development of MM120 (lysergic acid diethylamide LSD D-tartrate) as a potential treatment for adults ...










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com